MCKESSON CORP（MCK）の決算・業績分析
MCKESSON CORPの2025年有価証券報告書をAI分析。売上高$359.1B(+16.2%)。営業利益$4.4B。Industrials。
目次
MCKESSON CORPの2025年度 業績サマリー
MCKESSON CORP（証券コード: MCK）の2025年度決算・業績分析。売上高は$359.1B（前年比+16.2%）。営業利益は$4.4B（前年比+13.1%）。純利益は$3.3B（前年比+9.8%）。有価証券報告書を基に、業績変化の要因・リスク・見通し・セグメント構成を AI が分析しました。
MCKESSON CORPの2024年度 注目ポイント
※ 直近の2025年度XBRLデータは取込済みですが、AI分析は2024年度の10-Kを対象としています。
- Revenue surged to $264.0B (+10.8% YoY) in FY2024, driven by growth across healthcare distribution and technology segments (XBRL).
- Operating income skyrocketed to $2.0B (+140.4% YoY), reflecting improved efficiency and cost management (XBRL).
- Net income jumped to $1.1B (+124.5% YoY), with a net margin of 0.4% (XBRL).
- Shareholder returns totaled $3.8B via dividends ($277M) and share repurchases ($3.5B) (XBRL).
- Net debt stood at $2.1B (0.9x EBITDA), indicating manageable leverage despite negative equity (-3.0%) (XBRL).
MCKESSON CORPの売上高変化の要因
- •Total revenue reached $264.0B in FY2024, a 10.8% YoY increase (XBRL). Historical data shows consistent growth from $208.4B (FY2020) to $264.0B (FY2024), though segment-specific revenue figures are not quantified in the provided data (10-K). The 10-K notes growth across U.S. Pharmaceutical and Prescription Technology Solutions segments but lacks detailed breakdowns (10-K).
MCKESSON CORPの営業利益変化の要因
- •Gross profit was $13.1B with a 5.0% gross margin (XBRL). Operating income rose to $2.0B (+140.4% YoY) at a 0.8% operating margin (XBRL). Net income reached $1.1B (+124.5% YoY) with a 0.4% net margin (XBRL). Cost of sales changes are unspecified, but the low operating margin suggests high operational expenses or pricing pressures (N/A).
MCKESSON CORPの事業リスクと対応
Opioid litigation and regulatory actions pose significant financial and reputational risks, with potential for long-term legal expenses and consent decrees (10-K).
Uninsured losses from pharmaceutical distribution risks (e.g., counterfeit drugs) could harm financial stability (10-K).
Uncertainty in legal outcomes (e.g., fines, injunctive relief) introduces unpredictable financial risks (10-K).
Regulatory measures targeting controlled substance distribution (e.g., opioid taxes) may increase costs and reduce profitability (10-K).
Costly legal disputes and regulatory proceedings, including ongoing opioid litigation, may result in substantial penalties or operational changes (10-K).
MCKESSON CORPの今後の見通し・業績予想
MCKESSON CORPの事業内容
MCKESSON CORP operates as a diversified healthcare services leader, generating revenue through the distribution of pharmaceuticals, medical-surgical supplies, and technology-enabled solutions for medication access and price transparency (10-K). Key segments include U.S. Pharmaceutical (drug distribution), Prescription Technology Solutions (digital health services), Medical-Surgical Solutions (supply chain), and International operations in Canada/Europe (10-K). The company serves pharmacies, hospitals, biopharma partners, and payors without significant customer concentration (10-K). Competitive advantages include technology platforms like McKesson Connect and strategic partnerships, such as the ClarusONE joint venture with Walmart for generic drug sourcing (10-K).
MCKESSON CORPのAI業績分析レポート（2024年度）
MCKESSON CORP (MCK) FY2024 Annual Report Analysis
Highlights
Business Overview
MCKESSON CORP is a diversified healthcare services leader, distributing pharmaceuticals, providing prescription technology solutions, and offering medical-surgical supplies (10-K). Key segments include U.S. Pharmaceutical, Prescription Technology Solutions, Medical-Surgical Solutions, and International operations (10-K). Competitive advantages include technology platforms like McKesson Connect and strategic partnerships (10-K).
Revenue Analysis
Total revenue grew to $264.0B in FY2024, a 10.8% YoY increase (XBRL). Historical data shows consistent growth from $208.4B (FY2020) to $264.0B (FY2024), though segment-specific revenue figures are not quantified (10-K).
Profitability Analysis
Balance Sheet Analysis
Cash Flow Analysis
Risks
Outlook
Management provided a Fiscal 2025 outlook in the 10-K, though specific guidance numbers are not included. Revenue growth is expected to continue based on historical CAGR of +5.8% (XBRL).
Industrialsの企業一覧
MCKESSON CORPと同じ「Industrials」セクターの企業